TLDR:
Belgian medtech Nyxoah secures €37.5 million EIB venture-debt financing to treat obstructive sleep apnea. The European Investment Bank (EIB) is providing venture debt financing to Nyxoah to develop innovative solutions for obstructive sleep apnea. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA.
Summary:
The European Investment Bank (EIB) is offering Belgium-based medtech Nyxoah €37.5 million in venture-debt financing to develop treatments for obstructive sleep apnea. Nyxoah plans to use the funding for research, development, and scaling up manufacturing capacity to meet demand in Europe and the US. The EIB’s support aligns with its priority to boost research and technological innovation in accordance with EU policies.
Nyxoah focuses on developing and commercializing innovative treatments for obstructive sleep apnea, a common sleep-disordered breathing condition associated with increased mortality risk and cardiovascular comorbidities. Their lead solution, the Genio system, is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for OSA.
EIB Vice-President Robert de Groot expressed pride in supporting innovation in the life sciences and medtech industry in Belgium, highlighting Nyxoah’s groundbreaking approach. Nyxoah CEO Olivier Taelman expressed excitement and gratitude for the EIB’s support, which will aid in commercializing Genio in the US and Europe and increasing production capacity.
The €37.5 million facility provided by EIB is divided into three tranches, with disbursement subject to certain conditions. Venture debt financing from EIB benefits from the guarantee under the InvestEU Life Sciences program, supporting fast-growing innovative companies like Nyxoah. Nyxoah’s focus on addressing obstructive sleep apnea with cutting-edge technology highlights their commitment to improving patient outcomes worldwide.
